PTC wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920; $111M upfront

PTC THERAPEUTICS, INC.

Deal: $111M upfront plus up to $100M milestones ($80M on accelerated approval, $20M on traditional FDA approval).
ST-920 is a one-time AAV gene therapy; BLA submission for accelerated approval expected Q4 2026.
Phase 1/2 STAAR data showed positive eGFR slope at 52 weeks; durability up to 4.5 years in earliest patient.
Close expected late Q3/early Q4 2026, subject to bankruptcy court approval, antitrust review, and customary conditions.
PTC expects no impact on 2026 cash flow break-even; leverages existing rare disease commercial infrastructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.